Biotech Expert Brad Loncar Discusses Sector, ETFs
Biotech industry expert Brad Loncar discusses his approach to investing in biotech stocks and key current drivers in the sector. Brad also offers his perspective on broad-based biotech ETFs and explains the index behind the Loncar Cancer Immunotherapy ETF (CNCR). Nate & Jason spotlight the First …
Biotech ETFs in Focus
Brad Loncar, Head of Loncar Investments, joins us in studio to spotlight the index behind the Loncar Cancer Immunotherapy ETF (CNCR) and discuss the innovation occurring in cancer treatment. Nate and Conor also explain why ETFs can be an excellent way to access the biotech space in general.
Episode 147 - July 11, 2025
On this week’s episode, Eric Schmidt, Brad Loncar, Tim Opler and Tess Cameron kick off with a discussion on the surgein biotech M&A, with 2025 almost matching 2024’s deal count and surpassing it in value ($40B YTD vs $30B), highlighting recent deals like Merck’s acquisition of Verona and AbbVie’s p…
Episode 150 - August 1, 2025
On this week's episode, Daphne Zohar, Josh Schimmer, Brian Skorney, Paul Matteis, Sam Fazeli, Brad Loncar, and Matt Gline cover top news surrounding Trump's pricing letters to 17 major pharma companies demanding U.S. price cuts on new drugs, and the relevance to his MFN initiative. They also touch …
Episode 154 - September 12, 2025
On this week’s episode, Chris Garabedian, Tess Cameron, EricSchmidt, Sam Fazeli, and Brad Loncar open with a look at the market environment as biotech sees its first IPO since February -- LB Pharma -- and financings, including Maze’s $150M PIPE and Rapport’s $250M follow-on. The co-hosts discuss im…
Episode 156 - September 26, 2025
On this week’s episode, Sam Fazeli, Eric Schmidt, PaulMatteis, Brian Skorney, and Brad Loncar dive into what was a positive week for biotech, marked by M&A, offerings, and compelling clinical data, spotlighting Pfizer’s acquisition of Metsera. The conversation shifts to data, starting with UniQure’…
Episode 157 - October 3, 2025
On this week’s episode, Eric Schimidt, Sam Fazeli, Brian Skorney, Yaron Werber, and Brad Loncar open withmacro news including Pfizer’s deal with the White House on U.S. drug manufacturing and pricing, which helped shelve the Most Favored Nation pricing and looming tariffs. The co-hosts agreed it wa…
U.S. Science Summit: Listen to BiotechTV founder Brad Loncar's opening remarks at the inaugural U.S. Science Summit
He describes the format and goals of the event.
Episode 190 - July 24, 2026
On this week's episode, Josh Schimmer, Brian Skorney, Eric Schmidt, and Brad Loncar kick off with IPOs and raises, including Scribe's IPO, the first preclinical biotech IPO since the COVID era, which priced in a modest but upsized deal. The group also covers Mentari's additional $200 million raise …
Episode 200 - October 23, 2026
On this week's 200th episode, Daphne Zohar, Brad Loncar, Chris Garabedian, Sam Fazeli, Eric Schmidt, Josh Schimmer, Matt Gline, and special guest former Silence CEO Ali Mortazavi kicked off by reflecting on five years of Biotech Hangout, including the show's role as an “open door” resource for thos…
MOTORE DI RICERCA PODCAST
Puoi utilizzare il nostro sito Web per cercare podcast3,835,030ed episodi197,371,853per persone, luoghi o argomenti.
If I have seen further than others, it is by listening to podcasts and standing upon the shoulders of
giants.
‐ Isaac "Llamacorn" Newton
MODIFICA
Grazie, ci hai aiutato a mantenere aggiornato il database dei podcast.
